The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats
- 31 January 2008
- journal article
- Published by Elsevier BV in Neuropharmacology
- Vol. 54 (1), 226-234
- https://doi.org/10.1016/j.neuropharm.2007.03.007
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Food Intake Regulates Oleoylethanolamide Formation and Degradation in the Proximal Small IntestineJournal of Biological Chemistry, 2007
- Prevalence of Fatty Liver in Children and AdolescentsPediatrics, 2006
- Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese ratsNeuropharmacology, 2005
- Stearoylethanolamide exerts anorexic effects in mice via downregulation of liver stearoyl‐coenzyme A desaturase‐1 mRNA expressionThe FASEB Journal, 2004
- Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α)Journal of Biological Chemistry, 2004
- The Role of Stearoyl-CoA Desaturase in Body Weight RegulationTrends in Cardiovascular Medicine, 2004
- Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight LossScience, 2002
- Oleoyl-CoA Is the Major de NovoProduct of Stearoyl-CoA Desaturase 1 Gene Isoform and Substrate for the Biosynthesis of the Harderian Gland 1-Alkyl-2,3-diacylglycerolPublished by Elsevier BV ,2001
- Leptin receptor missense mutation in the fatty Zucker ratNature Genetics, 1996
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959